Hostname: page-component-76fb5796d-vfjqv Total loading time: 0 Render date: 2024-04-26T11:34:10.433Z Has data issue: false hasContentIssue false
  • English
  • Français

5-httlpr polymorphism in patients with depression and the treatment response to citalopram.

Published online by Cambridge University Press:  16 April 2020

L. Vavrusova ,
V. Repiska  and
T. Braxatorisova
L. Vavrusova
Affiliation:
Depatrment of Psychiatry, University Hospital Ruzinov, Bratislava, Slovak Republic
V. Repiska
Affiliation:
Department of Biology, Comenius University, Bratislava, Slovak Republic
T. Braxatorisova
Affiliation:
Department of Biology, Comenius University, Bratislava, Slovak Republic

Abstract

Core share and HTML view are not available for this content. However, as you have access to this content, a full PDF is available via the ‘Save PDF’ action button.

The relationship of the serotonin transporter gene promoter region polymorphism (5-HTTLPR) to antidepressant response was examined in 50 patients receiving protocolized treatment for depression with citalopram. Patients were treated for up to 12 weeks assessed weekly with clinical ratings and measurements (HAMD-17, MADRS, CGI).

Samples from 50 subjects with Major depressive disorder - recurrent episode (DSM-IV) were analyzed for 5-HTT-promotor polymorphism.

Patients with genotype II responded more rapidly and better to treatment with citalopram in comparison to those who did not responded or were only partial responders.

Allelic variation of 5-HTTLPR may contribute to the variable response of patients treated with selective serotonin reuptake inhibitor.

Type
Poster Session 2: Depressive Disorders
Information
European Psychiatry , Volume 22 , Issue S1: 15th AEP Congress - Abstract book - 15th AEP Congress , March 2007 , pp. S247
Copyright
Copyright © European Psychiatric Association 2007
Submit a response

Comments

No Comments have been published for this article.